Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dialysis-related carnitine disorder.

S Susan Hedayati1

  • 1Department of Medicine, Division of Nephrology, Veterans Affairs North Texas Health Care System, Dallas, Texas 75216-7167, USA. susan.hedayati@med.va.gov

Seminars in Dialysis
|August 9, 2006
PubMed
Summary

L-carnitine is vital for fatty acid metabolism, but kidney disease and dialysis deplete it. Supplementation benefits are debated, though it may help specific anemic dialysis patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney Function Decline in Sickle Cell Disease: Associations with Renin-Angiotensin System Inhibitors.

Kidney360·2026
Same author

Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD).

Kidney international·2026
Same author

A Practical Primer on How to Detect and Treat Depression in CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025
Same author

Cognitive Impairment: A Novel Risk Factor for Rapid Kidney Function Decline and Incident CKD in Middle-Aged Adults.

Kidney360·2025
Same author

Severe Mental Illness in CKD: Why it Matters.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025
Same author

Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2024

Area of Science:

  • Biochemistry
  • Nephrology
  • Nutritional Science

Background:

  • L-carnitine facilitates fatty acid beta-oxidation by transporting fatty acids into mitochondria.
  • Kidneys maintain plasma L-carnitine levels via tubular reabsorption, a function impaired in end-stage renal disease (ESRD).
  • ESRD and dialysis lead to carnitine deficiency due to lost synthesis and non-selective clearance.

Purpose of the Study:

  • To evaluate the efficacy of L-carnitine supplementation in managing dialysis-related symptoms.
  • To address the conflicting results from previous studies on L-carnitine's benefits in dialysis patients.

Main Methods:

  • Review of numerous studies investigating L-carnitine supplementation for dialysis-related symptoms.
  • Analysis of study limitations including lack of randomization, control groups, and standardized outcome measures.
  • Identification of specific patient subgroups where L-carnitine may be beneficial.

Main Results:

  • Conflicting results exist regarding L-carnitine's effectiveness in alleviating symptoms like hypotension, heart failure, muscle weakness, and low exercise capacity.
  • Many studies are limited by methodological flaws.
  • Evidence suggests potential benefit in selected anemic dialysis patients with high erythropoietin needs.

Conclusions:

  • The role of L-carnitine supplementation in dialysis patients requires further rigorous investigation.
  • Current evidence is insufficient to broadly recommend L-carnitine for all dialysis-related symptoms.
  • L-carnitine may be a useful adjunct therapy for specific anemic dialysis patients unresponsive to other treatments.

Related Experiment Videos